指南与共识膀胱癌与上尿路尿路上皮癌

非肌层浸润性膀胱癌的诊断与治疗:AUA/SUO 指南 2024 年修订版

Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment.
指南 / 共识 · J Urol · 2024-01-24

美国泌尿外科学会(AUA)/泌尿肿瘤学会(SUO)对非肌层浸润性膀胱癌(NMIBC)指南进行 2024 年修订,检索 2019 年 7 月至 2023 年 5 月文献,纳入 75 篇符合标准文献,更新了变异组织学、膀胱癌诊断后尿液标志物、膀胱内治疗、BCG 维持治疗、增强膀胱镜检查和未来方向等陈述。

要点

  • 本指南为 AUA/SUO 非肌层浸润性膀胱癌指南 2024 年修订版,整合 2019 年 7 月至 2023 年 5 月新发表文献。
  • 更新涉及变异组织学、诊断后尿液标志物、膀胱内治疗、BCG 维持、增强膀胱镜和未来方向等陈述。
  • 证据强度分为 A(高)、B(中)、C(低),分别支持强推荐、中等推荐或有条件推荐;证据不足时提供临床原则和专家意见。

核心结论

  • 本指南旨在基于当前可得证据提高临床医生对 NMIBC 患者的评估和治疗能力。
  • 未来研究对进一步支持或完善这些陈述以改善患者照护至关重要。

研究设计与样本

  • 美国泌尿外科学会(AUA)/泌尿肿瘤学会(SUO)指南修订,通过 AUA 修订流程审阅并整合新发表文献。
  • 检索 2019 年 7 月至 2023 年 5 月文献,识别 1918 篇摘要,其中 75 篇符合纳入标准。
  • 证据充足时,证据体强度评级为 A(高)、B(中)或 C(低),分别支持强推荐、中等推荐或有条件推荐;证据不足时提供临床原则和专家意见。

主要发现

  • 更新了关于变异组织学、膀胱癌诊断后尿液标志物、膀胱内治疗、BCG 维持治疗、增强膀胱镜检查和未来方向的陈述。
  • 根据需要进一步修订了方法和参考文献部分。

临床怎么用

  • 原文未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this American Urological Association (AUA)/Society of Urologic Oncology (SUO) guideline amendment is to provide a useful reference on the effective evidence-based treatment strategies for non-muscle invasive bladder cancer (NMIBC). MATERIALS AND METHODS: In 2023, the NMIBC guideline was updated through the AUA amendment process in which newly published literature is reviewed and integrated into previously published guidelines in an effort to maintain currency. The amendment allowed for the incorporation of additional literature released since the previous 2020 amendment. The updated search gathered literature from July 2019 to May 2023. This review identified 1918 abstracts, of which 75 met inclusion criteria.When sufficient evidence existed, the body of evidence was assigned a strength rating of A (high), B (moderate), or C (low) in support of Strong, Moderate, or Conditional Recommendations. In the absence of sufficient evidence, additional information is provided as Clinical Principles and Expert Opinions. RESULTS: Updates were made to statements on variant histologies, urine markers after diagnosis of bladder cancer, intravesical therapy, BCG maintenance, enhanced cystoscopy, and future directions. Further revisions were made to the methodology and reference sections as appropriate. CONCLUSIONS: This guideline seeks to improve clinicians' ability to evaluate and treat patients with NMIBC based on currently available evidence. Future studies will be essential to further support or refine these statements to improve patient care.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Holzbeierlein JM, Bixler BR, Buckley DI, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment. J Urol. 2024. PMID: 38265030. doi:10.1097/JU.0000000000003846

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。